Literature DB >> 23419487

Without therapeutic drug monitoring, there is no personalized cancer care.

J H Beumer1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23419487     DOI： 10.1038/clpt.2012.243

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  16 in total

1.  Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.

Authors:  Jan H Beumer; Venkateswaran C Pillai; Robert A Parise; Susan M Christner; Brian F Kiesel; Michelle A Rudek; Raman Venkataramanan
Journal:  Br J Clin Pharmacol       Date:  2015-09-19       Impact factor: 4.335

2.  Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet?

Authors:  S Percy Ivy; Jan H Beumer
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

3.  High-Tech Drugs in Creaky Formulations.

Authors:  Maikel Herbrink; Bastiaan Nuijen; Jan H M Schellens; Jos H Beijnen
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

Review 4.  Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.

Authors:  Huixin Yu; Neeltje Steeghs; Cynthia M Nijenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

5.  Pharmacotherapy in cancer patients with HIV/AIDS.

Authors:  J H Beumer; R Venkataramanan; M A Rudek
Journal:  Clin Pharmacol Ther       Date:  2014-01-17       Impact factor: 6.875

6.  A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy.

Authors:  Jai N Patel; Bert H O'Neil; Allison M Deal; Joseph G Ibrahim; Gary B Sherrill; Oludamilola A Olajide; Prashanti M Atluri; John J Inzerillo; Christopher H Chay; Howard L McLeod; Christine M Walko
Journal:  Oncologist       Date:  2014-08-12

Review 7.  Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

Authors:  Jan H Beumer; Edward Chu; Carmen Allegra; Yusuke Tanigawara; Gerard Milano; Robert Diasio; Tae Won Kim; Ron H Mathijssen; Li Zhang; Dirk Arnold; Katsuki Muneoka; Narikazu Boku; Markus Joerger
Journal:  Clin Pharmacol Ther       Date:  2018-09-11       Impact factor: 6.875

8.  Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study.

Authors:  Jacqueline S L Kloth; Heinz-Josef Klümpen; Huixin Yu; Karel Eechoute; Caroline F Samer; Boen L R Kam; Alwin D R Huitema; Youssef Daali; Aeilko H Zwinderman; Bavanthi Balakrishnar; Roelof J Bennink; Mark Wong; Jan H M Schellens; Ron H J Mathijssen; Howard Gurney
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

Review 9.  Computational oncology--mathematical modelling of drug regimens for precision medicine.

Authors:  Dominique Barbolosi; Joseph Ciccolini; Bruno Lacarelle; Fabrice Barlési; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

10.  Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.

Authors:  Venkateswaran C Pillai; Raman Venkataramanan; Robert A Parise; Susan M Christner; Roberto Gramignoli; Stephen C Strom; Michelle A Rudek; Jan H Beumer
Journal:  Drug Metab Dispos       Date:  2013-08-02       Impact factor: 3.922
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.